[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"platelet\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:platelet":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100562590","phase-3-canadian-critical-care-comparative-effectiveness-platform-100562590",false,"NCT06605144","Canadian Critical Care Comparative Effectiveness Platform","Canadian Critical Care Comparative Effectiveness Platform(e) d'Évaluation Clinique Comparée en Soins Critiques (CEPEC)","CEPEC","VASOPRESSOR DOMAIN There is no minimum age limit in the Vasopressor Domain.\n\nInclusion criteria:\n\n1. Ongoing vasopressor infusion to treat hypotension, or would be used to treat clinician-defined hypotension as part of usual care;\n2. MAP \\\u003C75 mmHg at any point;\n3. Patient expected to be in the ICU for \\>24 hours.\n\nExclusion criteria:\n\n1. Treating team does not have equipoise for at least two contiguous MAP target ranges in the CEPEC Vasopressor Domain;\n2. Acute traumatic brain injury (within 7 days or ongoing active treatment for elevated intracranial pressure);\n3. Acute subarachnoid hemorrhage (within 21 days);\n4. Acute spinal cord injury (within 7 days of injury or ongoing vasopressor therapy for suspected spinal cord ischemia);\n5. Lung, heart, liver, kidney transplant recipient (within 7 days);\n6. Patient expected to become an organ donor (Donor Neurologic Death - DND or Donation After Circulatory Death - DCD);\n7. More than 24 hours since meeting inclusion criteria in the ICU;\n8. Previously randomized into the CEPEC Vasopressor Domain or a confounding trial.\n\nPLATELET DOMAIN\n\nInclusion criteria:\n\n1. Adult patients (age ≥18 years) admitted to the ICU;\n2. Latest platelet count in this hospital admission \\\u003C50×109\u002FL;\n3. Planned to undergo a specified low-moderate bleeding risk invasive procedure.\n\nExclusion criteria:\n\n1. Ongoing major hemorrhage requiring blood products and\u002For surgical\u002F radiological intervention;\n2. Intracranial hemorrhage within prior 72 hours;\n3. Contraindications to platelet transfusion (e.g. thrombotic microangiopathies, heparin-induced thrombocytopenia, recent history of immune thrombocytopaenia, congenital platelet function defects);\n4. Known advance decision of refusing blood\u002Fblood component transfusions;\n5. Acute promyelocytic leukemia (APML);\n6. Death perceived as imminent or admission for palliation;\n7. Previously randomized into the CEPEC Platelet Domain or the T4P Trial;\n8. Fulfilled all the inclusion criteria and none of the exclusion criteria ≥72 hours.\n\nNUTRITION DOMAIN\n\nInclusion criteria:\n\n1. Critically ill patients ≥18 years of age;\n2. Are invasively mechanically ventilated (including endotracheal tube or tracheostomy);\n3. Orogastric\u002Fnasogastric tube in place; or have an in dwelling percutaneous gastric tube (with confirmed placement);\n4. Treating team has started or has the intention of providing enteral nutrition.\n\nExclusion criteria:\n\n1. Patients who have had gastrointestinal (GI) surgery; in the last 3 months and deemed not ready to receive possible bolus nutrition;\n2. Bowel obstruction or ischemia; active;\n3. Has a post-pyloric small bowel feeding tube;\n4. Active GI bleeding;\n5. Patient who is chronically receiving enteral nutrition.","ALL","18 Years",{"count":20,"type":21},5500,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The Canadian Critical Care Comparative Effectiveness Platform(e) d'Évaluation Clinique Comparée en soins Critiques (CEPEC) is an international multi-centered randomized adaptive platform clinical trial. CEPEC will evaluate supportive care interventions that are used routinely in intensive care units throughout the world.",[27,28,29,30],"Intensive Care Unit ICU","Vasopressor","Platelet","Nutrition",[32,33,28,29,34],"ICU","Adaptive platform trial","Enteral nutrition","RECRUITING","2026-06-25",{"date":38,"type":39},"2026-06-30","ACTUAL",{"date":41,"type":39},"2025-03-23",{"date":43,"type":21},"2030-06-30",{"name":45,"class":46},"Université de Sherbrooke","OTHER",9,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":65,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100599368","impact-of-iv-iron-on-bleeding-symptoms-in-iron-deficient-patients-with-inherited-bleeding-disorders-100599368","NCT07083583","Impact of IV Iron on Bleeding Symptoms in Iron Deficient Patients With Inherited Bleeding Disorders","Impact of IV Iron on Bleeding Symptoms in Iron Deficient Patients With Inherited Bleeding Disorders: a Single-arm Prospective Observational Study","IRON-BD","Inclusion Criteria:\n\n1. Males and Females \\> 15 years of age\n2. Diagnosed with an Inherited Bleeding Disorder (Von Willebrand disease, platelet disorders, factor deficiencies, or bleeding disorder of unknown cause)\n3. Evidence of Iron Deficiency (Ferritin \\\u003C 50 ng\u002FmL)\n4. Receiving IV iron at Hemophilia Center of Western Pennsylvania\n5. Willingness to have blood drawn\n6. Willing to return to clinic 3 months post infusion for final blood draw, bleeding and quality of life assessments.\n\nExclusion Criteria:\n\n1. Previous thrombosis, VTE History.\n2. Platelet count \\\u003C 100,000 \\* 109\u002FL\n3. Concomitant use of antiplatelet drugs, anticoagulants, aspirin, NSAIDs.","15 Years",{"count":58,"type":21},40,"OBSERVATIONAL","This is a prospective, single-arm, single-center observational study evaluating the impact of intravenous (IV) iron replacement in patients with inherited bleeding disorders and iron deficiency (ferritin \\\u003C50ng\u002FdL). Subjects will undergo baseline bleeding assessments, quality-of-life measures, and laboratory tests before receiving standard-of-care IV iron. Follow-up blood work and questionnaires will be conducted post-replacement to assess for changes",[62,63,29,64],"Bleeding Disorders","Iron","Bleeding",[66,67,68],"Iron deficiency","bleeding disorder","platelet function","2025-10-01",{"date":71,"type":39},"2025-10-03",{"date":73,"type":39},"2025-08-08",{"date":75,"type":21},"2027-10-01",{"name":77,"class":46},"Nicoletta C Machin",1]